Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
26 June, 2018 01:06 IST
Zydus receives USFDAs final nod for Eletriptan HCl tablets
Source: IRIS | 19 Jun, 2017, 10.32AM
Comments  |  Post Comment

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Eletriptan Hydrobromide Tablets, 20 mg (base) and 40 mg (base).

The drug which is used in the treatment of migraine will be produced at the group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad.

The group now has more than 120 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company gained Rs 7.15, or 1.36%, to trade at Rs 532.55. The total volume of shares traded was 33,144 at the BSE (10.24 a.m., Monday).



Cadila Healthcare Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
NHPC signs PPA with UPPCL for Kishanganga project - 25-Jun-2018 16:47
Info Edge enters into agreement with Soft Bank for joint investment - 25-Jun-2018 16:43
Ratnamani Metals & Tubes receives order worth Rs 1.25 bn - 25-Jun-2018 16:38
Jet Airways to acquire 75 Boeing 737 MAX Aircrafts - 25-Jun-2018 16:35
MCX signs MoU with IMC to Synergise Efforts - 25-Jun-2018 16:16
Voltas JV lays ground to build 1st manufacturing unit - 25-Jun-2018 12:37
Vikas Ecotech to set up India's First 2-EHTG unit in Dahej - 25-Jun-2018 12:24
MBL Infra substantially completes two projects - 25-Jun-2018 12:19
Tata Comm partners with Singapore based IoT star-up W-Locate - 25-Jun-2018 10:26
DHFL expects 30% growth in home loan disbursements from Karnataka - 22-Jun-2018 11:22
KPIT, Kinetiq announce strategic life sciences collaboration - 22-Jun-2018 11:09
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer